|
1000
|
Abstract/Summary
|
-
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Purpose</jats:title>
<jats:p>Radiopharmaceutical therapies targeting fibroblast activation protein (FAP) have shown promising efficacy against many tumor types. But radiopharmaceuticals alone in most cases are insufficient to completely eradicate tumor cells, which can partially be attributed to the protective interplay between tumor cells and cancer-associated fibroblasts (CAFs). The C-X-C chemokine receptor type 4/C-X-C motif chemokine 12 (CXCR4/CXCL12) interaction plays an important role in orchestrating tumor cells and CAFs. We hereby investigated the feasibility and efficacy of [<jats:sup>177</jats:sup>Lu]Lu-DOTAGA.(SA.FAPi)<jats:sub>2</jats:sub>, a FAP-targeting radiopharmaceutical, in combination with AMD3100, a CXCR4 antagonist, in a preclinical murine model of triple-negative breast cancer (TNBC).</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Public database was first interrogated to reveal the correlation between CAFs’ scores and the prognosis of TNBC patients, as well as the expression levels of FAP and CXCR4 in normal tissues and tumors. In vitro therapeutic efficacy regarding cell proliferation, migration, and colony formation was assessed in BALB/3T3 fibroblasts and 4T1 murine breast cancer cells. In vivo therapeutic efficacy was longitudinally monitored using serial <jats:sup>18</jats:sup>F-FDG, [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04, and [<jats:sup>68</jats:sup>Ga]Ga-DOTA-Pentixafor PET/CT scans and validated using tumor sections through immunohistochemical staining of Ki-67, α-SMA, CXCR4, and CXCL12. Intratumoral abundance of myeloid-derived suppressive cells (MDSCs) was analyzed using flow cytometry in accordance with the PET/CT schedules. Treatment toxicity was evaluated by examining major organs including heart, lung, liver, kidney, and spleen.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>CAFs’ scores negatively correlated with the survival of TNBC patients (<jats:italic>p</jats:italic> < 0.05). The expression of CXCR4 and FAP was both significantly higher in tumors than in normal tissues. The combination of [<jats:sup>177</jats:sup>Lu]Lu-DOTAGA.(SA.FAPi)<jats:sub>2</jats:sub> and AMD3100 significantly suppressed cell proliferation, migration, and colony formation in cell culture, and exhibited synergistic effects in 4T1 tumor models along with a decreased number of MDSCs. PET/CT imaging revealed lowest tumor accumulation of <jats:sup>18</jats:sup>F-FDG and [<jats:sup>18</jats:sup>F]AlF-NOTA-FAPI-04 on day 13 and day 14 after treatment started, both of which gradually increased at later time points. A similar trend was observed in the IHC staining of Ki-67, α-SMA, and CXCL12.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>The combination of [<jats:sup>177</jats:sup>Lu]Lu-DOTAGA.(SA.FAPi)<jats:sub>2</jats:sub> and AMD3100 is a feasible treatment against TNBC with minimal toxicity in main organs.</jats:p>
</jats:sec>
|
